direct healthcare professional communications (dhpcs)
In the case of urgent and/or important safety issues, Direct Healthcare Professional Communications are used to notify health care professionals.
An overview of DHPCs sent in 2013 can be found below. All DHPCs are in PDF format.
MabThera - In very rare circumstances MabThera can lead to severe skin reactions (15 April 2013)
Nulojix - Risk of acute graft rejection associated with rapid corticosteroid taper when using Nulojix (8 April 2013)
Vistide - Recall Vistide leads to shortage in supply (8 March 2013)
Thalidomide Celgene - Important safety information for the clinical use of Thalidomide Celgene and practical details on the restrictions for prescribing and dispensing Thalidomide
This DHPC was not sent in the Netherlands, because the product has not been brought onto the market in the Netherlands. Consequently, no national Pregnancy Prevention Programme has been assigned to this product.
Prolia - Risk of atypical femoral fracture with Prolia (22 February 2013)
Xagrid - Increased risk of cardiovascular adverse events when using Xagrid (25 January 2013)
Tredaptive - Treatment with Tredaptive should be discontinued (23 January 2013)
Gilenya - Altered recommendations Gilenya (22 January 2013)
Angiox - Dosing regimens for Angiox need to be followed carefully (15 January 2013)
Tredaptive - Re-evaluation of efficacy and risks of Tredaptive (10 January 2013)
Pradaxa - New contraindication for Pradaxa (4 January 2013)